Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Published:2021-06-01 Issue:6 Volume:7 Page:937
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Sun Lova¹,Hsu Miles¹,Cohen Roger B.¹,Langer Corey J.¹,Mamtani Ronac¹,Aggarwal Charu¹

Affiliation:

1. Abramson Cancer Center, Division of Hematology/Oncology, University of Pennsylvania, Philadelphia

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2778198/jamaoncology_sun_2021_ld_210004_1623352037.98711.pdf

Reference6 articles.

1. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042.;Herbst;Annals of Oncology,2019

2. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.;Liu;Cancer Lett,2020

3. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA.;Coelho;Immunity,2017

4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.;Mok;Lancet,2019

5. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.;Kartolo;Cancer Treat Res Commun,2021

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to immunotherapy;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer;Med;2024-08

3. Current perspectives of KRAS in non-small cell lung cancer;Current Problems in Cancer;2024-08

4. Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis;Swiss Medical Weekly;2024-07-25

5. KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways;Cells;2024-07-19